Skip to content
You can now search across every topic, entity and event.What's new
Pandemics and Biosecurity
16JUN

WHO defers vaccine-sharing pact to 2027

3 min read
10:26UTC

WHA79 deferred the Pandemic Agreement's vaccine-sharing annex to 2027, leaving the treaty's equity core inoperative during an emergency that has no licensed product to share.

ScienceDeveloping
Key takeaway

The treaty's vaccine-sharing core stays unfinished until 2027, just as an outbreak with no licensed product needs it.

The 79th World Health Assembly (WHA79) deferred adoption of the Pandemic Agreement's Pathogen Access and Benefit-Sharing (PABS) annex to WHA80 in May 2027, or to an earlier special session if a text is ready 1. The next negotiating round, the seventh Intergovernmental Working Group session (IGWG7), is set for 6 to 17 July 2026 2. PABS is the part of the treaty meant to guarantee that countries which share virus samples receive fair access to the vaccines made from them. Tedros Adhanom Ghebreyesus said real progress had been made, and member states cited a need for more time 3.

This is the second slip in a month: negotiators had already agreed to extend the PABS talks at the resumed sixth IGWG session on 1 May . The annex has stalled because high-income states resist binding sharing obligations they fear will constrain their own manufacturers, the same fault line that has dogged every benefit-sharing negotiation since the 2007 dispute over Indonesian H5N1 samples.

The timing gives the deferral its edge. The treaty's vaccine-sharing core stays inoperative at the exact moment a novel-species emergency with no licensed countermeasure would have tested it. If a Bundibugyo vaccine reaches trials this year, there is still no binding legal route to push doses to the low-income countries carrying the outbreak; allocation stays at the discretion of manufacturers and the buyers WHO can pay first. The world adopted the treaty in 2024 and, two years on, still cannot do the one thing its equity advocates designed it to do.

Deep Analysis

In plain English

When a new dangerous virus emerges, countries need to share samples of it quickly so that scientists around the world can study it and start making vaccines. The problem is that in past pandemics, like H1N1 in 2009, the countries that shared their virus samples did not get any of the vaccines that were made from those samples. Rich countries bought them all first. PABS (Pathogen Access and Benefit-Sharing) is meant to be the rule that fixes this: countries share samples and in return get guaranteed access to vaccines produced from them. The 79th World Health Assembly, which met in Geneva in May 2026, pushed the decision on PABS to a 2027 meeting because member states cannot agree on how the rules would work in practice. During the current Bundibugyo Ebola outbreak, there is no licensed vaccine for this species at all; the PABS negotiations apply to future outbreaks where a sharing-and-access mechanism could make the difference between equitable and inequitable vaccine distribution.

First Reported In

Update #4 · Ebola triples, response misfires

Konrad-Adenauer-Stiftung Geneva Multilateral Dialogue· 24 May 2026
Read original
Different Perspectives
Indian Council of Medical Research
Indian Council of Medical Research
ICMR deployed a team to Kerala within hours of the 11 June Nipah confirmation in Kozhikode, tracing roughly 100 contacts including 58 healthcare workers; three days without fresh positives suggest containment of a pathogen with no licensed vaccine and a case-fatality rate of 40 to 75 percent.
ECDC / European Union
ECDC / European Union
ECDC's Week 23 Communicable Disease Threats Report carried four simultaneous non-Ebola signals including the first peer-reviewed evidence of Dermatophilus congolensis sexual transmission, local mpox clade Ib European spread, and the Dermatophilus rapid risk assessment due 23 June. European import risk for Bundibugyo is assessed as very low.
United States (HHS / State Department)
United States (HHS / State Department)
Washington committed $270 million bilaterally to the response on 12 June while its 30-day entry ban on DRC, Uganda and South Sudan nationals, extended to green-card holders on 5 June, expired around 17 June unresolved. The CDC's R0=2.51 modelling is the sharpest analytical contribution to the response from any national agency.
World Health Organization
World Health Organization
DON607's publication on 13 June provides the 695-case international reference and attributes the treatment trial design to national leadership rather than WHO advisory consensus; the WHO co-authors the Continental Strategic Plan with Africa CDC but holds no enforcement lever over the US entry ban expiring 17 June.
Uganda Ministry of Health
Uganda Ministry of Health
Diana Atwine's ministry traced the 14-imported-case Uganda cluster using protocols rehearsed in the 2022 Sudan ebolavirus containment of 142 cases in 113 days; Uganda co-authorises the treatment trial and Bwera border lab reduces cross-border confirmation to same-day. Nineteen confirmed cases with five from onward Kampala transmission test whether the Sudan playbook transfers.
DRC Ministry of Health
DRC Ministry of Health
Kinshasa's 14 June bulletin counted 782 confirmed cases with 45.9 percent isolated, a figure DRC's health minister has linked directly to ongoing attacks on treatment facilities rather than community resistance. DRC co-leads the clinical trial now under national authority, a regulatory posture that keeps Geneva's timeline advisory, not binding.